Keyword: Seqirus

Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.

CSL’s new brand positioning is actually its first—and it comes after more than 100 years in business.

Flu vaccine specialist Seqirus grew sales 26% in the six months leading up to Dec. 31, driven by a portfolio shift.

Here is some other vaccine news of note for the week.

During the two-plus years of Seqirus' existence, the company has worked to hone its portfolio and boost output of next-gen cell culture flu vaccines.

Seqirus' adjuvanted flu vaccine Fluad is finally set for routine use in the U.K. because the current shot isn't working for the elderly.

Health experts presented flu vaccination guidelines stressing there's no difference in safety for shots given people allergic to eggs.

Here's some other vaccine news of note for the week.

The egg-based production process might have made this season's flu shot only 10% effective.

Seqirus will invest £40 million into its U.K. site, adding about 100 jobs so it can shorten production time for its Fluad influenza vaccine.